Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System

OBJECTIVE: To evaluate the risk of myasthenia gravis (MG) associated with immune checkpoint inhibitors (ICI). METHODS: Adverse event (AE) reports related to MG, myasthenic syndrome, and MG crisis for durvalumab, atezolizumab, pembrolizumab, nivolumab, avelumab, and ipilimumab in the US FDA Adverse E...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Qingli, Wang, Hui, Ren, Xiaolei, Zhuo, Yue, Peng, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587957/
https://www.ncbi.nlm.nih.gov/pubmed/37724594
http://dx.doi.org/10.1002/cam4.6559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587957/
https://www.ncbi.nlm.nih.gov/pubmed/37724594
http://dx.doi.org/10.1002/cam4.6559

Ejemplares similares